Annotation Detail

Information
Associated Genes
RET
Associated Variants
RET p.Met918Thr (p.M918T) ( ENST00000340058.6, ENST00000713926.1, ENST00000355710.8, ENST00000615310.5 )
RET p.Met918Thr (p.M918T) ( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 )
Associated Disease
thyroid gland medullary carcinoma
Source Database
CIViC Evidence
Description
Cabozantinib significantly prolonged progression-free survival (PFS) versus placebo in patients with progressive, metastatic medullary thyroid cancer (HR 0.28). Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (HR 0.23). Patients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53). The RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7710
Gene URL
https://civic.genome.wustl.edu/links/genes/42
Variant URL
https://civic.genome.wustl.edu/links/variants/113
Rating
4
Evidence Type
Predictive
Disease
Thyroid Gland Medullary Carcinoma
Evidence Direction
Supports
Drug
Cabozantinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27525386
Drugs
Drug NameSensitivitySupported
CabozantinibSensitivitytrue